Crizotinib Treatment for advanced non-small cell lung cancer patients: a budget impact analysis based in Thailand.

CONCLUSION: Despite its value of treatment in ALK positive patients, crizotinib can be affordable for Thai patients within upper middle or high economic status. Availability for all patients under current payment models is limited. PMID: 28277868 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research